Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Michael C. Heinrich, Christopher L. Corless, George D. Demetri et al. · Journal of Clinical Oncology · 2003 · 2.3K citations

Medicine, Molecular Medicine, Oncology +17

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Charles D. Blanke, Cathryn Rankin, George D. Demetri et al. · Journal of Clinical Oncology · 2008 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +13

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>KIT</i>

Charles D. Blanke, George D. Demetri, Margaret von Mehren et al. · Journal of Clinical Oncology · 2008 · 1K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne et al. · European Journal of Cancer · 2006 · 899 citations

Medicine, Molecular Genetics, Oncology +14